EC Number   |
Inhibitors |
Structure  |
|---|
   3.4.22.38 | more |
not inhibitory are pepstatin, phenylmethylsulfonylfluoride, EDTA, 1,10-phenanthroline |
 |
| 3.4.22.38 | more |
not inhibitory are phenylmethylsulfonylfluoride, disopropyfluorophosohate, soybean inhibitor, pepstatin A |
|
| 3.4.22.38 | more |
physiological inhibitors of osteoclast differentiation and activation, such as osteoprotegerin, interleukin-6, INF-gamma, can also directly suppress cathepsin K expression |
|
| 3.4.22.38 | more |
structure-based design of diverse pyrimidine-based scaffolds for inhibitor design |
|
| 3.4.22.38 | more |
inhibitory activities of N-cyano-tetrahydro-pyridazine derivatives, docking studies, overview |
|
| 3.4.22.38 | more |
inhibitor development and structure-activity relationships, overview |
|
| 3.4.22.38 | more |
metabolism and pharmacokinetics, overview |
|
| 3.4.22.38 | more |
no inhibition of cathepsin K inhibitor III |
|
| 3.4.22.38 | more |
construction of a three-dimensional pharmacophore model for cathepsin K inhibitor screening and development using the enzyme crystal structure complexed with a ketoamide inhibitor, docking and inhibitor binding structure, validation of pharmacophore hypothesis, overview |
|
| 3.4.22.38 | more |
P2/S2 and P3/S3 interaction of cathepsin K inhibitors with pyrrolopyrimidine scaffold and structure of the common intermediate, overview |
|
